Skip to main content

Coronavirus (COVID-19): Visitor Restrictions, Resources, and Updates

View Latest Updates Visitor Restrictions
Explore URMC
menu
Wilmot Cancer Institute / Cancers We Treat / Skin Cancers / Your Team

Adrienne Victor, M.D., M.S.

Contact Information

Phone Numbers

Appointment: (585) 275-5823

Administrative: (585) 275-9319

URMFGA member of the University of Rochester Medical Faculty Group

groupAn Accountable Health Partner

assignmentAccepting New Patients

Locations

Wilmot Cancer Institute Oncology
601 Elmwood Ave
Rochester, NY 14642-0001

Oncology: (585) 275-5823

Faculty Appointments

Patient Care Setting

Cancer

Credentials

Specialties

  • Internal Medicine - American Board of Internal Medicine
  • Medical Oncology - American Board of Internal Medicine

Education

2012
MD | University of Illinois College of Medicine at Urba

Post-doctoral Training & Residency

07/01/2015 - 07/10/2018
Fellowship in Hematology/Oncology at University of Rochester Medical Center

07/01/2013 - 06/30/2015
Residency in Internal Medicine at University of Texas Health Science Center at San Antonio

07/01/2012 - 06/30/2013
Internship in Internal Medicine at University of Texas Health Science Center at San Antonio

VIEW ALL expand_more

Awards

2017
Bennett Travel Award
Location: University of Rochester

2011
Andrew and Hortense Call Barr Award

2009 - 2011
Ukrainian Medical Association of North America Scholarship Awards

2009 - 2009
Rural Medicine Preceptorship Award
Sponsor: St. Mary's Good Samaritan Hospital, Centralia IL.

2004 - 2006
Intramural Research Training Award
Sponsor: National Institute on Drug Abuse
Location: Baltimore, MD

2003
Summer Undergraduate Research Program,Training Award
Sponsor: Pomona College
Location: Claremont, CA

VIEW ALL expand_more

Clinical Trials

S1801 A Phase II Randomized Study of Adjuvant vs. Neoadjuvant MK-3475 (Pembrolizumab) for Clinically Detectable Stage III-IV High-Risk Melanoma

Lead Researcher: Adrienne Victor

This phase II trial studies how pembrolizumab works before and after surgery in treating patients with stage III-IV high-risk melanoma. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving pembrolizumab before and after surgery may work better in treating melanoma.

View Study Details

A031702: A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)

Lead Researcher: Adrienne Victor

This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that have spread to other places in the body. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cabozantinib, nivolumab, and ipilimumab may work better in treating patients with genitourinary tumors that have no treatment options compared to giving cabozantinib, nivolumab, or ipilimumab alone.

View Study Details

A Phase 2 Study of INCMGA00012 in Participants With Metastatic Merkel Cell Carcinoma (POD1UM-201)

Lead Researcher: Adrienne Victor

The purpose of this study is to assess the clinical activity and safety of INCMGA00012, a monoclonal antibody, in participants with metastatic merkel cell carcinoma (MCC).

View Study Details

Publications

Journal Articles

8/2018
Archibald WJ, Meacham PJ, Williams AM, Baran AM, Victor AI, Barr PM, Sahasrahbudhe DM, Zent CS. "Management of melanoma in patients with chronic lymphocytic leukemia." Leukemia research.. 2018 Aug 0; 71:43-46. Epub 2018 Jul 06.

12/2006
Chen GJ, Harvey BK, Shen H, Chou J, Victor A, Wang Y. "Activation of adenosine A3 receptors reduces ischemic brain injury in rodents." Journal of neuroscience research.. 2006 Dec 0; 84(8):1848-55.

VIEW ALL PUBLICATIONS